CD33 and neoplasm: Also, in this cohort, correlations between the therapy response and the expression in tumor cells of myeloid markers, the presence of which reflects an aberrant immunophenotype for leukemia with lymphoid origins [39,40], were found: Moderate correlations with CD33 (r = 0.38) and CD15 (r = 0.41); and weak correlations with CD117 (r = 0.25) and CD65 (r = 0.29) (Figure 3B).